
Pfizer appoints inflammation and immunology head
pharmafile | April 1, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Charles Reay Mackay, Pfizer
Professor Charles Reay Mackay is joining US pharma giant Pfizer as the chief scientific officer of its inflammation and immunology research unit.
Mackay will report directly to Dr José-Carlos Gutiérrez-Ramos, group vice president of BioTherapeutics R&D, and will be based in Pfizer’s US R&D hub in Cambridge.
Mackay joins Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University where he was chair of Diabetes.
Mackay has also held biotech leadership positions at LeukoSite and Millennium Therapeutics in Massachusetts.
Gutiérrez-Ramos says: “Professor Mackay brings to Pfizer a unique combination of scientific expertise, academic credentials and entrepreneurial spirit. His deep commitment to drug discovery and his unique skill set will help advance Pfizer’s position as a global leader in inflammation and a collaborator of choice within the Cambridge community and beyond.”
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






